Telomere-controlled senescence;Les telomeres et le vieillissement des cellules

Medecine/Sciences

Volumn 16, Issue 4, 2000, Pages 473-480

  Ouellette, Michel M ^a   Savre Train, Isabelle ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P16; PROTEIN P53; RNA; RNA DIRECTED DNA POLYMERASE; TELOMERASE;

AGING; CARCINOGENESIS; CATALYSIS; CELL DIVISION; CELL SURVIVAL; DNA SYNTHESIS; HUMAN; PROTEIN EXPRESSION; SENESCENCE; SHORT SURVEY; TELOMERE;

EID: 0034107778     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/1678     Document Type: Short Survey

References (48)

1. Martin GM, Sprague CA, Epstein CJ. Replicative lifespan of cultivated human cells: effect of donor's age, tissue and genotype. Lab Invest 1970; 23: 86-92.
2. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell derived inhibitors of DNA synthesis using an expression screen. Exp tell Res 1994; 211: 90-8.
3. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci USA 1996; 93: 13742-7.
4. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92: 9363-7.
5. LePeuch C, Dorée M. Le temps du cycle cellulaire. Med Sci 2000; 16: 461-8.
6. El-Deiry WS. p21/p53, cellular growth control and genomic integrity. Curr Top Microbiol Immunol 1998; 227: 121-37.
7. Stein GH, Beeson M, Gordon L. Failure to phosphorylate the retinoblastoma gene product in senescent human fibroblasts. Science 1990; 249: 666-9.
8. Wright WE, Shay JW. The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol 1992; 27: 383-9.
9. Blackburn EH. Telomeres: no end in sight. Cell 1994; 77: 621-3.
10. Ancelin K, Castellazzi M, Gislon E. Télomères et cancer: les barrières tombent. Med Sci 2000; 16: 481-6.
11. Van Steensel B, de Lange T. Control of telomere length by the human telomeric protein TRF1. Nature 1997; 385: 740-3.
12. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 1999; 283: 1321-5.
13. Gire V, Wynford-Thomas D. La sénescence dans les cellules humaines: un obstacle au développement tumoral? Med Sci 1999; 15: 1096-104.
14. Decary S, Mouly V, Hamida CB, Sautet A, Barbet JP, Butler-Brown GS. Replicative potential and telomere length in human skeletal muscle: implications for satellite cell-mediated gene therapy. Hum Gene Ther 1997; 8: 1429-38.
15. Counter CM, Avilion AA, LeFeuvre CE, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992; 11: 1921-9.
16. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279: 349-52.
17. Morales CP, Holt SE, Ouellette M, et al. Lack of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat Genet 1999; 21: 115-8.
18. Allsopp RC, Vaziri H, Patterson C, et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci USA 1992; 89: 10114-8.
19. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990; 346: 866-8.
20. Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdorp PM. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci USA 1994; 91: 9857-60.
21. Chang E, Harley CB. Telomere length and reolicative aging in human vascular tissues. Proc Natl Acad Sci USA 1995; 92: 11190-4.
22. Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 1989; 59: 521-9.
23. Makarov VL, Hirose Y, Langmore JP. Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell 1997; 88: 657-66.
24. McElligott R, Wellinger RJ. The terminal DNA structure of mammalian chromosomes. EMBO J 1997; 16: 3705-14.
25. Ulaner GA, Giudice, LC. Developmental regulation of telomerase activity in human fetal tissues during gestation. Mol Hum Reprod 1997; 3: 769-73.
26. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 1996; 18: 173-9.
27. Feng JL, Funk WD. Wang SS, et al. The RNA component of human telomerase. Science 1995; 269: 1236-41.
28. Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit nomologs from fission yeast and human. Science 1997; 277: 955-9.
29. Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998; 396: 84-8.
30. Brenner AJ, Stampfer MR, Aldaz CM. Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. Oncogene 1998; 17: 199-205.
31. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9: 138-41.
32. Reddel RR, Bryan TM, Murnane JP. Immortalized cells with no detectable telomerase activity. Biochemistry 1997; 62: 1254-62.
33. Shay JW, Bacchetti S. A survev of telomerase activity in human cancer. Eur Cancer 1997; 33: 787-91.
34. Olovnikov AM. A theory of marginotomy The incomplete copying of template margin in enzymic synthesis or polynucleotides and biological significance of the phenomenon. J Theor Biol 1973; 41: 181-90.
35. Di Leonardo A, Linke SP, Clarkin K, Wahl GM. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 1994; 8: 2540-51.
36. Robles SJ, Adami, GR. Agents that cause DNA double strand breacks lead to p16-ink4a enrichment and to premature senescence of normal fibroblasts. Oncogene 1998; 6: 1113-23.
37. Bourns BD, Alexander MK, Smith AM, Zakian VA. Sir proteins, Rif proteins, and Cdc13p bind Saccharomvces telomeres in vivo. Mol Cell Biol 1998; 18: 5600-8.
38. Marcand S, Gilson E, Shore D. A protein-counting mechanism for telomere length regulation in yeast. Science 1997; 275: 986-90.
39. Gravel S, Larrivee M, Labrecque P, Wellinger RJ. Yeast Ku as a regulator of chromosomal DNA end structure. Science 1998; 280: 741-4.
40. Griffith JD, Comeau L, Rosenfield S, et al. Mammalian telomeres end in a large duplex loop. Cell 1999; 97: 503-14.
41. Lavin MF, Shiloh Y. The genetic defect in ataxia-telangiectasia. Annu Rev Immunol 1997; 15: 177-202.
42. Khanna KK, Keating KE, Kozlov S, et al. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet 1998; 20: 398-400.
43. Simbulan-Rosenthal CM, Rosenthal DS, Luo R, Smulson ME. Poly(ADP-ribosyl)ation of p53 during apoptosis in human osteosarcoma cells. Cancer Res. 1999; 59: 2190-4.
44. Vaziri H, West MD, Allsopp RC, et al. ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase. EMBO J 1997; 16: 6018-33.
45. Smith S, Giriat I, Schmitt A, de Lange T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 1998; 282: 1484-7.
46. Hsu HL, Gilley D, Blackburn EH, Chen DJ. Ku is associated with the telomere in mammals. Proc Natl Acad Sci USA 1999; 96: 12454-8.
47. Featherstone C, Jackson SP. Ku, a DNA repair protein with multiple cellular functions? Mutat Res 1999; 434: 3-15.
48. Lenhard K, Chang S, Lee HW, et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 1999; 96: 701-12.